Cost parameters | Mean | Standard error | Distribution | Ref. |
---|---|---|---|---|
Medication, laboratory and diagnostic tests costs | ||||
Pegylated interferon alfa-2a + Ribavirin (per week) | 3,150 | 630 | Gamma | [35] |
Pegylated interferon alfa-2b + Ribavirin (per week) | 3,150 | 630 | Gamma | [35] |
Investigation and monitoring | 16,277 | 3,255 | Gamma | [34] |
Direct medical cost for complication treatment | ||||
Costs of chronic HCV infection (per year) | 65,640 | 19,723 | Gamma | [33] |
Costs of compensated cirrhosis (per year) | 73,532 | 18,605 | Gamma | [33] |
Costs of decompensated cirrhosis (per year) | 138,141 | 18,996 | Gamma | [33] |
Costs of hepatocellular carcinoma (per year) | 168,899 | 11,601 | Gamma | [33] |
Direct non-medical cost for complication treatment | ||||
Costs of chronic HCV infection (per year) | 4,303 | 430.3 | Gamma | |
Costs of compensated cirrhosis (per year) | 4,216 | 421.6 | Gamma | |
Costs of decompensated cirrhosis (per year) | 5,823 | 582.3 | Gamma | |
Costs of hepatocellular carcinoma (per year) | 9,516 | 951.6 | Gamma |